8月27日，诺泰生物获东海证券买入评级，近一个月诺泰生物获得8份研报关注。
研报预计2024-2026年归母净利润分别为4.12/5.61/7.16亿。研报认为，公司中报业绩显著超预期，受益于GLP-1等多肽行业的快速发展，公司竞争优势持续扩大，预计公司业绩仍将保持快速增长态势。
风险提示：市场竞争风险、汇率波动风险、研发风险、集采降价超预期风险等。
诺泰生物获东海证券买入评级，业绩显著超预期
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha